Key result
GDF-15 demonstrated high diagnostic accuracy for distinguishing intensive care unit-acquired weakness from non-ICU-AW, with a pooled diagnostic odds ratio of 21.39 and an area under the curve of 0.88.
Why the study?
Growth differentiation factor-15 may be a potential biomarker for intensive care unit-acquired weakness, but quantitative analysis of its levels and diagnostic utility was needed.
Does Growth differentiation factor-15 (GDF-15) accurately diagnose intensive care unit-acquired weakness (ICU-AW)?
Meta-Analysis (n=647)
Does Growth differentiation factor-15 (GDF-15) accurately diagnose intensive care unit-acquired weakness (ICU-AW)?
GDF-15 demonstrates strong diagnostic performance as a biomarker for identifying intensive care unit-acquired weakness.
Answers are grounded in this paper and cite their sources.
GDF-15 may enable earlier ICU-AW detection in practice; confirms high pooled diagnostic accuracy in meta-analysis.
Background: Growth differentiation factor-15 (GDF-15) may be a potential biomarker for intensive care unit-acquired weakness (ICU-AW). In this study, we aimed to quantitative analysis the levels of GDF-15 in patients with ICU-AW and in non-ICU-AW, and then to determine its potential diagnostic utility. Methods: Two researchers separately conducted a systematic search of the relevant studies up to May 2023 in various literature databases (PubMed, Cochrane, Web of Science, Embase, and CINAHL). Studies were selected according to the inclusion and exclusion criteria, and quality evaluation of the included studies was conducted by using QUADAS-2 provided by Review Manager 5.3. The software packages Meta Disc (C1.4) and Stata17.0 were used for the meta-analysis. The data were combined with fixed-effects model, and the summary receiver operating characteristic curve was drawn to evaluate the overall diagnostic accuracy of GDF-15. Results: We identified 6 eligible studies comprising 401 patients with ICU-AW. The sensitivity, specificity, diagnostic odds ratio (DOR), and area under the curve (AUC) for the discriminative performance of GDF-15 as a diagnostic biomarker were 0.82 (95% confidence interval (CI):0.78-0.86), 0.83 (95% CI: 0.61-0.88), 21.39 (95% CI: 13.36-34.24), and 0.88 (95% CI: 0.85-0.91), respectively. Conclusion: GDF-15 is a candidate biomarker in diagnosing of ICU-AW from non-ICU-AW.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) conducted a meta-analysis in Intensive care unit-acquired weakness (ICU-AW) (n=647). Growth differentiation factor-15 (GDF-15) vs. Non-ICU-AW was evaluated on Diagnostic accuracy (Diagnostic Odds Ratio) of GDF-15 for ICU-AW (DOR 21.39, 95% CI 13.36-34.24). GDF-15 demonstrated high diagnostic accuracy for distinguishing intensive care unit-acquired weakness from non-ICU-AW, with a pooled diagnostic odds ratio of 21.39 and an area under the curve of 0.88.
Synapse has enriched 10 related papers. Consider them for comparative context: